DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2010/01 12041 A1 Ahmad Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2010/01 12041 A1 Ahmad Et Al US 201001 12041A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/01 12041 A1 Ahmad et al. (43) Pub. Date: May 6, 2010 (54) ENDOXIFEN COMPOSITIONS AND Publication Classification METHODS (51) Int. Cl. (75) Inventors: Ateeq Ahmad, Wadsworth, IL st 4: :08: (US); Shoukath M. Ali, Vernon A69/10 (2006.015 Hills, IL (US); Moghis U. Ahmad, CD7C 2.3/10 (2006.015 Wadsworth, IL (US); Saifuddin A6IP35/00 (2006.015 Sheikh, Waukegan, IL (US): Imran C07C 215/08 (2006.015 Ahmad, Libertyville, IL (US) A69/48 (2006.01) A6IR 9/28 (2006.01) C d Address: E.S."9 Ave w- e. (52) U.S. Cl. ......... 424/450; 514/648; 424/484:564/324; 2275 DEMINGWAY, SUITE 310 424/463; 424/474 MIDDLETON, WI 53562 (US) (57) ABSTRACT (73) Assignee: UNA PHARMACEUTICALS The present invention provides compositions containing INC., Libertyville, IL (US) 9 endoxifen, formulations and liposomes of endoxifen, meth s s ods of preparation of such agents and formulations, and use of 21) Appl. No.: 12/S15.261 Such agents and formulations for the treatment of breast can (21) Appl. No 9 cer and other breast diseases and diseases Susceptible to (22) PCT Filed: Nov. 21, 2007 endoxifen. In particular, the compositions of the present e af-l invention include liposomes, complexes, Vesicles, emulsions, micelles and mixed micelles of endoxifen in which the com (86). PCT No.: PCT/US07/8.5443 positions further contain any of a variety of neutral or charged S371 (c)(1) lipids and desirably, cholesterol and cholesterol derivatives, (2), (4) Date: Jan. 8, 2010 sterols, Z- and E-guggulsterones, phospholipids, fatty acids, s a V8 vitamin D, and vitamin E.The present invention also provides O O methods of preparing endoxifen. The present invention pro Related U.S. Application Data vides methods for treating and preventing breast cancer and (60) Provisional application No. 60/860,420, filed on Nov. other breast related diseases by administrating novel formu 21, 2006, provisional application No. 60/860,788, lations or compositions comprising a therapeutically effec filed on Nov. 22, 2006. tive amount of endoxifen. 1. Mg, THF 2O s 2. THF, Reflux (C) Patent Application Publication May 6, 2010 Sheet 1 of 3 US 2010/01 12041 A1 Figure 1 Patent Application Publication May 6, 2010 Sheet 2 of 3 US 2010/01 12041 A1 Figure 2 Br ... O so. OH O OO C-RT r 1. 2 3 r C O as 1. Mg, THF 2C -- 2. THF, Reflux O. O O O 8-) 3 4 5 y HCHN '. () level. (C) -gC OH Patent Application Publication May 6, 2010 Sheet 3 of 3 US 2010/01 12041 A1 Figure 3 N. / C.e.g. C CYP2D6 - C, O SULT1A1 O) CYP2C19,(CYP2b6, CYP2C9, CYP3A) O) OH Tamoxifen (TAM) 4-hydroxyTAM CYP3A45 (CYP2C9 + other CYP isoforms) N. / ON/ H oU/N C o CYP2D6 C o C e O C SULT1A1 OH N-desmethylTAM Endoxifen US 2010/01 12041 A1 May 6, 2010 ENDOXFEN COMPOSITIONS AND is present in higher concentration (12.4 ng/mL) than 4-OH METHODS tamoxifen (1 ng/mL) in the human plasma. The majority of genes affected by endoxifen are estrogen-regulated genes (8-9). Use of endoxifen e.g., in place of Tamoxifen, avoids 0001. This application claims priority to U.S. Provisional several metabolic steps that rely on CYP2D6. Application Ser. No. 60/860,420, filed Nov. 21, 2006, and 0007. A strong need exists for methods to treat and to 60/860,788, filed Nov. 22, 2006, both of which are incorpo prevent breast diseases without significant adverse systemic rated herein by reference. side effects, particularly in the premenoposal population. In particular, there is a need for breast cancer treatments and FIELD OF THE INVENTION preventatives that having reduced interactive effect with other medications. 0002. The invention relates to the use of endoxifen in the treatment of mammalian diseases. The invention also relates to liposomes and other formulations such as complexes, SUMMARY OF THE INVENTION vesicles, emulsions, micelles and mixed micelles of endox 0008. The present invention provides methods and com ifen, methods of preparation, and uses, e.g., in the treatment positions for the syntheses and use of active agents such as of human and animal breast diseases. The invention in par anticancer agents. The present invention relates to methods ticular relates to compositions comprising endoxifen-lipid and compositions related to the formulations and uses of complexes, methods of preparation, and their use for the endoxifen, particularly in applications related to the treat treatment of breast diseases, in particular benign and malig ment or prevention of cancer. nant breast disease, enhancing disease regression and reduc 0009. In some embodiments, the present invention pro ing risk of patients developing breast cancer. The invention vides a method of treating a disease, comprising, preparing a further relates to methods of preparing endoxifen and use of composition comprising a therapeutically active amount of endoxifen prepared by inventive method in the treatment of endoxifen and administering the composition. In some human and animal diseases. embodiments, the endoxifen is a free base, or is in the form of a salt. In some preferred embodiments, the endoxifen is in the BACKGROUND OF THE INVENTION form of a salt selected from the group of salts consisting of citrate, acetate, formate, oxalate, tartarate, trifluoroacetane, 0003. Every year more than 210,000 women in the United methane Sulfonate, phosphate, Sulfate, chloride, bromide, States develop breast cancer. One in eight women in the US iodide, lactate, and formate. In some embodiments, the will develop breast cancer during their lives. Approximately endoxifen is predominantly in a form selected from the group 70 percent of breast cancers are fueled by estrogen, and many consisting of E-isomer, Z-isomer, and a mixture of E- and are treated with Tamoxifen, a drug designed to block the Z-isomer. effects of estrogen in breast tissue. 0004 Tamoxifen is an anti-estrogenic drug prescribed for 0010. In some embodiments, method comprises preparing long-term, low dose therapy of breast cancer. It has been a complex comprising an anticancer drug and at least one widely used for more than 30 years for the endocrine treat lipid. In some embodiments, the anticancer drug is endoxifen. ment of all stages of hormone receptor-positive breast cancer In some embodiments, the compounds of the invention are (1-2). Tamoxifen has also been approved for the prevention of not complexed with a lipid. In some embodiments, the com breast cancer (3). In women, one of the adverse events asso pound is in the form of a free base or is in the form of a salt. ciated with Tamoxifen is hot flashes. The risk of hot flashes is 0011. In some embodiments, the present invention pro two to three-folds higher among women who take Tamoxifen vides methods of preparing endoxifen, comprising reacting a than it is for those who do not (4). Selective serotonin-re compound of Formula 5 with acid, wherein the compound of uptake inhibitor (SSRI) antidepressants are prescribed to treat formula 5 has the structure: hot flashes. However, some SSRIs, such as paroxetine and fluoxetine, are known to inhibit cytochrome P450(CYP) 2D6 (5), an enzyme that is important for the metabolism of many C drugs, including Tamoxifen. Our understanding of Tamox ifen metabolism and effect has changed clinical practice through the wide spread recognition that the co-prescription of drugs that inhibit CYP2D6 may compromise Tamoxifen efficacy. It is known that co-administration of paroxetine decreases the plasma concentration of an active metabolite of Tamoxifen, 4-hydroxy-N-desmethyl-Tamoxifen (endox OH ifen). 0005 Endoxifen is generated via CYP3A4-mediated N-demethylation and CYP2D6 mediated hydroxylation of Tamoxifen (see, e.g., FIG. 3). Any drug that can be substrate of CYP3A4 or CYP2D6, especially CYP2D6 e.g., SSRIs, can O decrease the level of endoxifen (6) and thus reduce the thera peutic benefits of Tamoxifen. Therefore, to avoid such drug drug interactions, one should not give them together. 0006 Recently, endoxifen has been shown to be anti-es trogenic in breast cancer cells and to be more potent than Tamoxifen (7). In patients treated with Tamoxifen, endoxifen US 2010/01 12041 A1 May 6, 2010 0012 and, after the reaction of the compound of Formula least one lipid. In preferred embodiments, the at least one 5 with acid, reacting the compound with methylamine. In lipid is selected from the group consisting of egg phosphati Some embodiments, the compound of Formula 5 is prepared dylcholine (EPC), egg phosphatidylglycerol (EPG), soy by reacting compound of formula 4 phosphatidylcholine (SPC), hydrogenated soy phosphatidyl choline (HSPC), dimyristoylphosphatidylcholine (DMPC), dimyristoylphosphatidylglycerol (DMPG), dipalmi toylphosohatidylcholine (DPPC), disteroylphosphatidylg lycerol (DSPG), dipalmitoylphosphatidylglycerol (DMPG), cholesterol (Chol), cholesterol sulfate and its salts (CS), cho lesterol hemisuccinate and its salts (Chems), cholesterol phosphate and its salts (CP), cholesterylphosphocholine and other hydroxycholesterol or amino cholesterol derivatives, cholesteryl Succinate, cholesteryl oleate, polyethylene glycol derivatives of cholesterol (cholesterol-PEG), coprostanol, cholestanol, cholestane, cholic acid, cortisol, corticosterone, hydrocortisone, and calciferol, E-guggulsterone, Z-guggul ac sterone, mixture of E- and Z-guggulsterone, monoglycerides, with a compound of Formula 3. diglycerides, triglycerides, carbohydrate-based lipids selected from a group consisting of galactolipid, mannolipid, galactolecithin, B-sitosterol, Stigmasterol, Stigmastanol, lanosterol, C.-spinasterol, lathosterol, campesterol, phos Br phatidylcholine, phosphatidylglycerol, phosphatidylethano lamine, phosphatidylserine, phosphatdylinositol, phospha tidic acid, and pegylated derivatives of distearoylphosphatidylglycerol, dipalmitoylphosphatidylg lycerol, dimyristoylphosphatidylglycerol, and dioleoylphos phatidylglycerol. O O 0016. In some embodiments, a composition according to the present invention comprises endoxifen, cholesterol and/or cholesterol derivatives, and one or more phospholipids. In Some preferred embodiments, the composition comprises a cholesterol derivative, and the cholesterol derivative is cho 0013.
Load more

Recommended publications
  • Glucocorticoid Receptor Blockade Normalizes Hippocampal Alterations and Cognitive Impairment in Streptozotocin- Induced Type 1 Diabetes Mice
    Neuropsychopharmacology (2009) 34, 747–758 & 2009 Nature Publishing Group All rights reserved 0893-133X/09 $32.00 www.neuropsychopharmacology.org Glucocorticoid Receptor Blockade Normalizes Hippocampal Alterations and Cognitive Impairment in Streptozotocin- Induced Type 1 Diabetes Mice ,1,2 1 1 2 2 Yanina Revsin* , Niels V Rekers , Mieke C Louwe , Flavia E Saravia , Alejandro F De Nicola , 1 1 E Ron de Kloet and Melly S Oitzl 1 Division of Medical Pharmacology, Leiden/Amsterdam Center for Drug Research, Leiden University Medical Center, Leiden, The Netherlands; 2 Laboratory of Neuroendocrine Biochemistry, IBYME, Buenos Aires, Argentina Type 1 diabetes is a common metabolic disorder accompanied by an increased secretion of glucocorticoids and cognitive deficits. Chronic excess of glucocorticoids per se can evoke similar neuropathological signals linked to its major target in the brain, the hippocampus. This deleterious action exerted by excess adrenal stress hormone is mediated by glucocorticoid receptors (GRs). The aim of the present study was to assess whether excessive stimulation of GR is causal to compromised neuronal viability and cognitive performance associated with the hippocampal function of the diabetic mice. For this purpose, mice had type 1 diabetes induced by streptozotocin (STZ) administration (170 mg/kg, i.p.). After 11 days, these STZ-diabetic mice showed increased glucocorticoid secretion and hippocampal alterations characterized by: (1) increased glial fibrillary acidic protein-positive astrocytes as a marker reacting to neurodegeneration, (2) increased c-Jun expression marking neuronal activation, (3) reduced Ki-67 immunostaining indicating decreased cell proliferation. At the same time, mild cognitive deficits became obvious in the novel object-placement recognition task.
    [Show full text]
  • Salivary 17 Α-Hydroxyprogesterone Enzyme Immunoassay Kit
    SALIVARY 17 α-HYDROXYPROGESTERONE ENZYME IMMUNOASSAY KIT For Research Use Only Not for use in Diagnostic Procedures Item No. 1-2602, (Single) 96-Well Kit; 1-2602-5, (5-Pack) 480 Wells Page | 1 TABLE OF CONTENTS Intended Use ................................................................................................. 3 Introduction ................................................................................................... 3 Test Principle ................................................................................................. 4 Safety Precautions ......................................................................................... 4 General Kit Use Advice .................................................................................... 5 Storage ......................................................................................................... 5 pH Indicator .................................................................................................. 5 Specimen Collection ....................................................................................... 6 Sample Handling and Preparation ................................................................... 6 Materials Supplied with Single Kit .................................................................... 7 Materials Needed But Not Supplied .................................................................. 8 Reagent Preparation ....................................................................................... 9 Procedure ...................................................................................................
    [Show full text]
  • Agonistic and Antagonistic Properties of Progesterone Metabolites at The
    European Journal of Endocrinology (2002) 146 789–800 ISSN 0804-4643 EXPERIMENTAL STUDY Agonistic and antagonistic properties of progesterone metabolites at the human mineralocorticoid receptor M Quinkler, B Meyer, C Bumke-Vogt, C Grossmann, U Gruber, W Oelkers, S Diederich and V Ba¨hr Department of Endocrinology, Klinikum Benjamin Franklin, Freie Universita¨t Berlin, Hindenburgdamm 30, 12200 Berlin, Germany (Correspondence should be addressed to M Quinkler; Email: [email protected]) Abstract Objective: Progesterone binds to the human mineralocorticoid receptor (hMR) with nearly the same affinity as do aldosterone and cortisol, but confers only low agonistic activity. It is still unclear how aldosterone can act as a mineralocorticoid in situations with high progesterone concentrations, e.g. pregnancy. One mechanism could be conversion of progesterone to inactive compounds in hMR target tissues. Design: We analyzed the agonist and antagonist activities of 16 progesterone metabolites by their binding characteristics for hMR as well as functional studies assessing transactivation. Methods: We studied binding affinity using hMR expressed in a T7-coupled rabbit reticulocyte lysate system. We used co-transfection of an hMR expression vector together with a luciferase reporter gene in CV-1 cells to investigate agonistic and antagonistic properties. Results: Progesterone and 11b-OH-progesterone (11b-OH-P) showed a slightly higher binding affinity than cortisol, deoxycorticosterone and aldosterone. 20a-dihydro(DH)-P, 5a-DH-P and 17a-OH-P had a 3- to 10-fold lower binding potency. All other progesterone metabolites showed a weak affinity for hMR. 20a-DH-P exhibited the strongest agonistic potency among the metabolites tested, reaching 11.5% of aldosterone transactivation.
    [Show full text]
  • Regulation of Intestinal Inflammation by Soybean and Soy-Derived Compounds
    foods Review Regulation of Intestinal Inflammation by Soybean and Soy-Derived Compounds Abigail Raffner Basson 1,2,* , Saleh Ahmed 2, Rawan Almutairi 3, Brian Seo 2 and Fabio Cominelli 1,2 1 Division of Gastroenterology & Liver Diseases, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA; [email protected] 2 Digestive Health Research Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA; [email protected] (S.A.); [email protected] (B.S.) 3 Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA; [email protected] * Correspondence: [email protected] Abstract: Environmental factors, particularly diet, are considered central to the pathogenesis of the inflammatory bowel diseases (IBD), Crohn’s disease and ulcerative colitis. In particular, the Westernization of diet, characterized by high intake of animal protein, saturated fat, and refined carbohydrates, has been shown to contribute to the development and progression of IBD. During the last decade, soybean, as well as soy-derived bioactive compounds (e.g., isoflavones, phytosterols, Bowman-Birk inhibitors) have been increasingly investigated because of their anti-inflammatory properties in animal models of IBD. Herein we provide a scoping review of the most studied disease mechanisms associated with disease induction and progression in IBD rodent models after feeding of either the whole food or a bioactive present in soybean. Keywords: inflammatory bowel disease; isoflavone; bioactive compound; isoflavones; inflammation; Crohn’s disease; western diet; plant-based Citation: Basson, A.R.; Ahmed, S.; Almutairi, R.; Seo, B.; Cominelli, F. Regulation of Intestinal Inflammation by Soybean and Soy-Derived Compounds. Foods 2021, 10, 774.
    [Show full text]
  • Quantification of Hair Corticosterone, DHEA and Testosterone As
    animals Article Quantification of Hair Corticosterone, DHEA and Testosterone as a Potential Tool for Welfare Assessment in Male Laboratory Mice Alberto Elmi 1 , Viola Galligioni 2, Nadia Govoni 1 , Martina Bertocchi 1 , Camilla Aniballi 1 , Maria Laura Bacci 1 , José M. Sánchez-Morgado 2 and Domenico Ventrella 1,* 1 Department of Veterinary Medical Sciences, University of Bologna, 40064 Ozzano dell’Emilia, BO, Italy; [email protected] (A.E.); [email protected] (N.G.); [email protected] (M.B.); [email protected] (C.A.); [email protected] (M.L.B.) 2 Comparative Medicine Unit, Trinity College Dublin, D02 Dublin, Ireland; [email protected] (V.G.); [email protected] (J.M.S.-M.) * Correspondence: [email protected]; Tel.: +39-051-2097-926 Received: 11 November 2020; Accepted: 14 December 2020; Published: 16 December 2020 Simple Summary: Mice is the most used species in the biomedical research laboratory setting. Scientists are constantly striving to find new tools to assess their welfare, in order to ameliorate husbandry conditions, leading to a better life and scientific data. Steroid hormones can provide information regarding different behavioral tracts of laboratory animals but their quantification often require stressful sampling procedures. Hair represents a good, less invasive, alternative in such scenario and is also indicative of longer timespan due to hormones’ accumulation. The aim of the work was to quantify steroid hormones in the hair of male laboratory mice and to look for differences imputable to age and housing conditions (pairs VS groups). Age influenced all analysed hormones by increasing testosterone and dehydroepiandrosterone (DHEA) levels and decreasing corticosterone.
    [Show full text]
  • The Effects of Dehydroepiandrosterone Sulfate on Counterregulatory Responses During Repeated Hypoglycemia in Conscious Normal Rats Darleen A
    The Effects of Dehydroepiandrosterone Sulfate on Counterregulatory Responses During Repeated Hypoglycemia in Conscious Normal Rats Darleen A. Sandoval, Ling Ping, Ray Anthony Neill, Sachiko Morrey, and Stephen N. Davis ␮ ⅐ ؊1 ⅐ ؊1 We previously determined that both antecedent hy- mol/l kg min ; P < 0.05). In summary, day-1 poglycemia and elevated cortisol levels blunt neu- antecedent hypoglycemia blunted neuroendocrine and roendocrine and metabolic responses to subsequent metabolic responses to next-day hypoglycemia. How- hypoglycemia in conscious, unrestrained rats. The adre- ever, simultaneous DHEA-S infusion during antecedent nal steroid dehydroepiandrosterone sulfate (DHEA-S) hypoglycemia preserved neuroendocrine and metabolic has been shown in several studies to oppose corticoste- counterregulatory responses during subsequent hypo- roid action. The purpose of this study was to determine glycemia in conscious rats. Diabetes 53:679–686, 2004 if DHEA-S could preserve counterregulatory responses during repeated hypoglycemia. We studied 40 male Sprague-Dawley rats during a series of 2-day protocols. he Diabetes Control and Complications Trial Day 1 consisted of two 2-h episodes of 1) hyperinsuline- mic (30 pmol ⅐ kg؊1 ⅐ min؊1) euglycemia (6.2 ؎ 0.2 established that intensive glucose control in type ANTE EUG), 2) hyperinsulinemic eug- 1 diabetic patients can slow the progression or ;12 ؍ mmol/l; n -plus simultaneous Tsignificantly reduce the onset of diabetic micro (8 ؍ lycemia (6.0 ؎ 0.1 mmol/l; n intravenous infusion of DHEA-S (30 mg/kg; ANTE EUG vascular complications (e.g., retinopathy, nephropathy, ؉ DHEA-S), 3) hyperinsulinemic hypoglycemia (2.8 ؎ neuropathy) (1). Unfortunately, the study also established ANTE HYPO), or 4) hyperinsulinemic that intensive glucose treatment causes an approximate ;12 ؍ mmol/l; n 0.1 -with simulta- threefold increase in the frequency of severe hypoglyce (8 ؍ hypoglycemia (2.8 ؎ 0.1 mmol/l; n neous intravenous infusion of DHEA-S (30 mg/kg; ANTE mia (2).
    [Show full text]
  • Plasma Corticosterone Levels in the Male Iguanid Lizard, Sceloporus Cyanogenys, Under Various Physiological Conditions
    W&M ScholarWorks Dissertations, Theses, and Masters Projects Theses, Dissertations, & Master Projects 1971 Plasma Corticosterone Levels in the Male Iguanid Lizard, Sceloporus cyanogenys, Under Various Physiological Conditions David Reams Daugherty College of William & Mary - Arts & Sciences Follow this and additional works at: https://scholarworks.wm.edu/etd Part of the Physiology Commons Recommended Citation Daugherty, David Reams, "Plasma Corticosterone Levels in the Male Iguanid Lizard, Sceloporus cyanogenys, Under Various Physiological Conditions" (1971). Dissertations, Theses, and Masters Projects. Paper 1539624722. https://dx.doi.org/doi:10.21220/s2-jk2d-cq40 This Thesis is brought to you for free and open access by the Theses, Dissertations, & Master Projects at W&M ScholarWorks. It has been accepted for inclusion in Dissertations, Theses, and Masters Projects by an authorized administrator of W&M ScholarWorks. For more information, please contact [email protected]. PLASMA CORTICOSTERONE LEVELS IN THE MALE IGUANID LIZARD, SCELOPORUS CYANOGENYS, UNDER VARIOUS PHYSIOLOGICAL CONDITIONS A Thesis Presented to The Faculty of the Department of Biology The College of William and Mary in Virginia In Partial Fulfillment Of the Requirements for the Degree of Master of Arts By David Reams Daugherty 1971 APPROVAL SHEET This thesis is submitted in partial fulfillment of the requirements for the degree of Master of Arts UT Author Approved , May 1971 Callard, Ph. D f - Robert E. L. Black, Ph. D. Jafid A. Simons, Ph. D ii S~0 4i04 -G«.~ : J lu ) ■ ACKNOWLEDGMENTS The writer wishes to express his appreciation to Professor Ian P. Callard, under whose direction this invest­ igation was conducted, for his preparation of the hypophy- sectomized and lesioned groups, and for his patient guidance and criticism throughout the investigation.
    [Show full text]
  • Progesterone Using ALZET Osmotic Pumps
    ALZET® Bibliography References on the Administration of Progesterone Using ALZET Osmotic Pumps Q8558: V. Joseph, et al. Progesterone decreases apnoea and reduces oxidative stress induced by chronic intermittent hypoxia in ovariectomized female rats. Exp Physiol 2020;105(6):1025-1034 Agents: Progesterone Vehicle: Cyclodextrin, 2-ß-Hydroxypropl-; Route: SC; Species: Rat; Pump: 2ML4; Duration: 28 days; ALZET Comments: Dose (4 mg/kg/day); Controls received mp w/ vehicle; animal info (Sprague-Dawley female rats (220-250g/57-70 days old)); post op. care (buprenorphine); Blood pressure measured via tail cuff method;93.3 mmHg - 105.2 mmHg;Progesterone aka prog; dependence; Q6232: S. F. Rosen, et al. T-Cell Mediation of Pregnancy Analgesia Affecting Chronic Pain in Mice. J Neurosci 2017;37(41):9819-9827 ALZET Comments: Estradiol, 17b-; Progesterone sulfate; SC; Mice; 2002; 14 days; Dose (17b-estradiol : 0.1 mg/kg/d, progesterone sulfate: 0.25 mg/kg/d, 0.1 mg/kg/d estradiol + 0.25 mg/kg/d progesterone); Controls received mp w/ vehicle; animal info (7-12 week old female C57BL/6J mice); replacement therapy (estradiol, ovariectomy); Therapeutic indication. Q6066: D. J. Morris, et al. Glucocorticoids and gut bacteria: "The GALF Hypothesis" in the metagenomic era. Steroids 2017;125(1-13 ALZET Comments: Chenodeoxycholic acid, progesterone, 11b-hydroxy-, corticosterone, deoxy-, corticosterone, 3α,5α-TH-, progesterone, 3α,5α-TH-11β-hydroxy-; SC; Rat; steroidal derivatives of corticosterone; Review presents the role of gut microbial metabolism of endogenous adrenocorticosteroids as a contributing factor in the etiology of essential hypertension. Q6204: S. McIlvride, et al. A progesterone-brown fat axis is involved in regulating fetal growth.
    [Show full text]
  • Mifepristone in the Central Nucleus of the Amygdala Reduces Yohimbine Stress-Induced Reinstatement of Ethanol-Seeking
    Neuropsychopharmacology (2012) 37, 906–918 & 2012 American College of Neuropsychopharmacology. All rights reserved 0893-133X/12 www.neuropsychopharmacology.org Mifepristone in the Central Nucleus of the Amygdala Reduces Yohimbine Stress-Induced Reinstatement of Ethanol-Seeking 1 1,2 1 1 ,1 Jeffrey A Simms , Carolina L Haass-Koffler , Jade Bito-Onon , Rui Li and Selena E Bartlett* 1 Preclinical Development Group, Ernest Gallo Clinic and Research Center at University of California San Francisco, Emeryville, CA, USA; 2 Clinical Pharmacology and Experimental Therapeutics, University of California San Francisco, Byers Hall, San Francisco, CA, USA Chronic ethanol exposure leads to dysregulation of the hypothalamic-pituitary-adrenal axis, leading to changes in glucocorticoid release and function that have been proposed to maintain pathological alcohol consumption and increase vulnerability to relapse during abstinence. The objective of this study was to determine whether mifepristone, a glucocorticoid receptor antagonist, plays a role in ethanol self-administration and reinstatement. Male, Long–Evans rats were trained to self-administer either ethanol or sucrose in daily 30 min operant self-administration sessions using a fixed ratio 3 schedule of reinforcement. Following establishment of stable baseline responding, we examined the effects of mifepristone on maintained responding and yohimbine-induced increases in responding for ethanol and sucrose. Lever responding was extinguished in separate groups of rats and animals were tested for yohimbine-induced reinstatement and corticosterone release. We also investigated the effects of local mifepristone infusions into the central amygdala (CeA) on yohimbine-induced reinstatement of ethanol- and sucrose-seeking. In addition, we infused mifepristone into the basolateral amygdala (BLA) in ethanol-seeking animals as an anatomical control.
    [Show full text]
  • REVIEW Rapid Non-Genomic Effects of Corticosteroids and Their Role in The
    153 REVIEW Rapid non-genomic effects of corticosteroids and their role in the central stress response Femke L Groeneweg, Henk Karst1, E Ron de Kloet and Marian Joe¨ls1 Department of Medical Pharmacology, Leiden Amsterdam Center for Drug Research and Leiden University Medical Center, Leiden University, Einsteinweg 55, 2333CC Leiden, The Netherlands 1Department of Neuroscience and Pharmacology, University Medical Center Utrecht, Universiteitsweg 100, 3584CG Utrecht, The Netherlands (Correspondence should be addressed to F L Groeneweg; Email: fl[email protected]) Abstract In response to a stressful encounter, the brain activates a neuroendocrine output within minutes. Knowledge on the comprehensive stress system that engages the organism in an identity of the receptors and secondary pathways mediating adaptive response to the threatening situation. This stress the non-genomic effects of corticosteroids on a cellular level system acts on multiple peripheral tissues and feeds back to the is accumulating. Interestingly, in many cases, an essential role brain; one of its key players is the family of corticosteroid for the ‘classical’ mineralocorticoid and glucocorticoid hormones. Corticosteroids affect brain functioning through receptors in a novel membrane-associated mechanism is both delayed, genomic and rapid, non-genomic mechanisms. found. Here, we systematically review the recent literature on The latter mode of action has long been known, but it is only non-genomic actions of corticosteroids on neuronal activity in recent years that the physiological basis in the brain is and functioning in selected limbic brain targets. Further, we beginning to be unravelled. We now know that corticoster- discuss the relevance of these permissive effects for cognition oids exert rapid, non-genomic effects on the excitability and and neuroendocrine control, and the integration of this novel activation of neurons in (amongst others) the hypothalamus, mode of action into the complex balanced pattern of stress hippocampus, amygdala and prefrontal cortex.
    [Show full text]
  • Corticosterone Using ALZET Osmotic Pumps
    ALZET® Bibliography References on the Administration of Corticosterone Using ALZET Osmotic Pumps Q8365: R. J. Perry, et al. Leptin's hunger-suppressing effects are mediated by the hypothalamic-pituitary-adrenocortical axis in rodents. Proc Natl Acad Sci U S A 2019;116(27):13670-13679 Agents: Corticosterone Vehicle: Saline; Route: CNS/CSF; Species: Mice; Pump: Not stated; Duration: 14 days; ALZET Comments: Dose (0.75 mg/d or 2.0 mg/d); 0.9% Saline used; animal info (8-12 weeks old, C57BL/6); diabetes; Q8070: Y. S. Lee, et al. Infrequent Feeding of Restricted Amounts of Food Induces Stress and Adipose Tissue Inflammation, Contributing to Impaired Glucose Metabolism. Int J Med Sci 2018;15(14):1667-1675 Agents: Corticosterone Vehicle: Saline; Route: SC; Species: Mice; Pump: 1003D; Duration: 3 days; ALZET Comments: Dose (15 ug/hr); Controls received mp w/ vehicle; animal info (Male, C57BL/6); dependence; Q6066: D. J. Morris, et al. Glucocorticoids and gut bacteria: "The GALF Hypothesis" in the metagenomic era. Steroids 2017;125(1-13 Agents: Chenodeoxycholic acid, progesterone, 11b-hydroxy-, corticosterone, deoxy-, corticosterone, 3α,5α-TH-, progesterone, 3α,5α-TH-11β-hydroxy- Vehicle: Not Stated; Route: SC; Species: Rat; Pump: Not Stated; Duration: Not Stated; ALZET Comments: steroidal derivatives of corticosterone; Review presents the role of gut microbial metabolism of endogenous adrenocorticosteroids as a contributing factor in the etiology of essential hypertension. Q6077: D. E. Livingstone, et al. Metabolic dysfunction in female mice with disruption of 5alpha-reductase 1. J Endocrinol 2017;232(1):29-36 Agents: Corticosterone Vehicle: DMSO; Propylene glycol; Route: Not Stated; Species: Mice; Pump: Not Stated; Duration: Not Stated; ALZET Comments: Dose (100 ug/day); 50% DMSO, 50% Propylene glycol used; animal info (Female 3-4 month old 5αR1-KO and wild-type mice); replacement therapy (glucocorticoid); Q6029: A.
    [Show full text]
  • Rat Prostatic Weight Regression in Reaction to Ketoconazole
    [CANCER RESEARCH 48, 6063-6068, November 1, 1988] Rat Prostatic Weight Regression in Reaction to Ketoconazole, Cyproterone Acetate, and RU 23908 as Adjuncts to a Depot Formulation of Gonadotropin-releasing Hormone Analogue Steven W. J. Lamberts,1 Piet Uitterlinden, and Frank H. de Jong Department of Medicine, Erasmus University, Rotterdam, The Netherlands ABSTRACT The effects of the s.c. administration of a depot formulation of the INTRODUCTION luteinizing hormone-releasing hormone (LHRH) analogue Zoladex were LHRH2 agonists initially stimulate pituitary gonadotropin studied in normal male rats, alone and in combination with three drugs with "antiandrogenic" action (ketoconazole, cyproterone acetate, and RU secretion resulting in an enhanced testosterone secretion, which 23908) on prostatic weight and on circulating hormone levels in order to is eventually followed by a depletion of pituitary LH stores and investigate whether these antiandrogens might prevent the LHRH-A- desensitization of LHRH receptors in the pituitary gland and of LH receptors in the gonads, and "medical" castration (1-4). induced initial increase in these parameters. These effects were compared with those caused by surgical castration. In addition the effects of the For these reasons treatment with LHRH-A results in inhibition antiandrogens on the activity of the hypothalamic-pituitary-adrenal axis of the growth of gonadal steroid-dependent tumors in humans were investigated. and animals (5-9). Several problems remain, however, with The depot LHRH analogue caused an initial increase in ventral pros regard to LHRH analogue treatment of male prostatic cancer tatic weight after 4 days but suppressed the prostatic and testicular patients: (a) the initial LHRH-induced increase in testosterone weights, the pituitary luteinizing hormone (1.11)content, and plasma LH secretion has been shown to cause a "flare-up" of the disease in and testosterone levels after 10 and 17 days.
    [Show full text]